Artrya (ASX:AYA) said that the Huntsville Hospital Heart Centre has agreed to participate in the company's SAPPHIRE study, which is to be conducted in three phases, to identify high-risk coronary artery disease patients with greater precision than traditional risk models, according to a Tuesday filing with the Australian bourse.
The company expects to launch the study in early 2026, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.